Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib or Penpulimab + RAI in Differentiated Thyroid Cancer
NCT04952493Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2021
- Primary completion
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anlotinib and penpulimab in differentiated thyroid cancer (DTC) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Objective Response Rate up to 24 months. Status: unknown.
02
Drugs
anlotinibpenpulimab
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT04952493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04952493.